Table 2.

Enrichment of immunosuppression in the mesenchymal glioblastoma subset

Number of cases; % of cases with mRNA overexpression
ProneuralMesenchymalClassicalNeural
Immunosuppressor/genePMID referencen = 141n = 160n = 147n = 96
Immunosuppressive cytokines and checkpointsGalectin-3/LGALS3226721522; 128; 1813; 96; 6
VEGF/VEGFA2054982116; 1126; 1632; 223; 3
IL-10/IL-10229818684; 339; 245; 313; 14
IL-23/IL-23A204041424; 321; 1312; 85; 5
TGF-β/TGFB195971275; 450; 3114; 102; 2
PD-1/SPATA21120908528; 2014; 958; 3927; 28
PD-L1/PD-L1221806780; 025; 1614; 105; 5
CTLA-4/CTLA-42057898212; 930; 198; 511; 11
Tumor-supportive macrophage chemotactic and skewing moleculesCSF-1/CSF147097713; 230; 194, 31, 1
CCL2/CCL2221627125; 453; 339; 67; 7
CCL-22/CCL-222051801610; 733; 2117; 1212; 13
CD163/CD163154783098; 660; 382; 111; 11
CD204/MSR1220832065; 453; 333; 28; 8
MIC-1/GDF15205347377; 543; 2725; 1714; 15
Arginase/ARG1206433029; 623; 1416; 1122; 23
CD47/CD471966652515; 1130; 1910; 719; 20
Immunosuppressive signaling pathwaysIL-6/IL-62324826532; 2383; 5216; 1115; 16
gp130/IL-6ST206108000; 025; 1617; 128; 8
Jak2226841056; 422; 149; 611; 11
STAT3/STAT3200537728; 631; 1926; 180; 0
Pim-1/PIM1223841974; 344; 2813; 96; 6
SOCS3/SOCS3108370555; 436; 2310; 73; 3
STAT5A/STAT5A128354784; 348; 3010; 72; 2
Markers of TregsCD4/CD4206052265; 457; 360; 09; 9
CD278/ICOS230261348; 623; 149; 69; 9
IDO/IDO1229326706; 425; 1614; 104; 4
FoxP3/FOXP3200681050; 00; 00; 00; 0

NOTE: Red denotes preferential statistically significant enrichment (P < 0.05) of mRNA expression in the comparison of the mesenchymal vs. proneural subset.